{
    "pmcid": "8223476",
    "qa_pairs": {
        "What method was used to enhance the binding affinity and neutralization potency of nanobodies targeting the SARS-CoV-2 spike protein?": [
            "CDR-swapping mutagenesis",
            "Traditional affinity maturation",
            "Random mutagenesis",
            "In vivo antibody generation"
        ],
        "What potential application is suggested for the matured nanobodies due to their favorable biophysical properties?": [
            "Therapeutic applications against SARS-CoV-2 and its variants",
            "Diagnostic applications for detecting multiple coronaviruses",
            "Vaccine development for broad coronavirus protection",
            "Environmental monitoring of viral particles"
        ],
        "What was a key finding regarding the specificity of the matured nanobodies?": [
            "They showed specificity for the SARS-CoV-2 RBD and did not cross-react with the SARS-CoV RBD.",
            "They cross-reacted with both SARS-CoV and MERS-CoV RBDs.",
            "They showed broad reactivity across multiple coronavirus RBDs.",
            "They were non-specific and bound to multiple viral proteins."
        ],
        "What was the initial method used to sort and select high-affinity nanobodies from the synthetic library?": [
            "Magnetic-activated cell sorting (MACS) followed by fluorescence-activated cell sorting (FACS)",
            "In vitro phage display",
            "Surface plasmon resonance (SPR)",
            "Biolayer interferometry (BLI)"
        ],
        "Which specific domain of the SARS-CoV-2 spike protein do the engineered nanobodies target?": [
            "Receptor-binding domain (RBD)",
            "N-terminal domain (NTD)",
            "Fusion peptide",
            "S2 subunit"
        ]
    }
}